US5470829A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical preparation
Assignee: Individual
•
Filing: 1993-03-25
•
Granted: 1995-11-28
•
Expires: 2013-03-25
Abstract
Abstract Pharmaceutical compositions which release the active ingredient slowly are based upon a growth factor or hormone as active ingredient and a means for effecting slow release of the active ingredient. Means for effecting slow release of the active ingredient comprise a conjugate or mixture of a first component and a second component. The first component is a protein other than the active ingredient for binding growth factors and hormones, and the second component is a biodegradable carrier.
Inventors
- 👤 Per Prisell
- 👤 Gunnar Norstedt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:04
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/30; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/593; A61K47/61; A61K47/62; A61K47/64; A61K47/642; A61K47/68; A61K47/6835; A61K47/6849; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; A61L; A61L31/00; A61L31/04; A61L31/043; A61L31/047; A61L31/14; A61L31/148; A61L31/16; A61L2300/00; A61L2300/40; A61L2300/412; A61L2300/414; A61L2300/43; A61L2300/80; A61L2300/802
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
221 words
In a method for administering ligand selected from the group consisting of growth factors and hormones to an animal comprising administering said ligand in combination with an adjuvant which controls the release of said ligand, said adjuvant comprising a biodegradable polymer and a receptor for said ligand, wherein said receptor is conjugated to a biodegradable polymer, the improvement wherein said receptor comprises (1) a protein for binding said ligand, said protein being selected from the group consisting of insulin-like growth factor-1-receptor; erythropoietin-receptor; insulin-like growth factor-2-receptor; insulin-receptor; platelet derived growth factor-receptor; fibroblast growth factor-receptor; colony stimulating growth factor-receptor; transforming growth factor-receptor; growth hormone-receptor; parathyroid hormone-receptor; calcitonin-receptor; estrogen-receptor; insulin-like growth factor serum binding protein; epidermal growth factor receptor; corticosteroid binding globulin; and bone morphogenic protein and (2) said biodegradable polymer is selected from the group consisting of alginates; hyaluronic acid and derivatives thereof: polyglycolide; copolymers of glycolide; copolymers of glycolide and L-lactide; copolymers of glycolide and trimethylene carbonate; polylactides; stereo-copolymers of polylactides; poly-L-lactide; poly-DL-lactide; copolymers of L-lactide and DL-lactide; copolymers of polylactide; copolymers of lactide and tetramethylglycolide; copolymers of lactide and trimethylene carbonate; copolymers of lactide and α-valerolactone; copolymers of lactide and ε-caprolactone; copolymers of polylactide and polyethylene oxide; copolymers of poly-β-hydroxybutyrate; polyurethanes; methylmethacrylate-N-vinyl pyrrolidone copolymers; and poly-p-dioxanone; said ligand being a ligand specific to said protein and being linked to said protein.
Claim 2
Dependent Claim
221 words
In a method for administering ligand selected from the group consisting of growth factors and hormones to an animal comprising administering said ligand in combination with an adjuvant which controls the release of said ligand, said adjuvant comprising a biodegradable polymer and a receptor for said ligand, wherein said receptor is conjugated to a biodegradable polymer, the improvement wherein said receptor comprises (1) a protein for binding said ligand, said protein being selected from the group consisting of insulin-like growth factor-1-receptor; erythropoietin-receptor; insulin-like growth factor-2-receptor; insulin-receptor; platelet derived growth factor-receptor; fibroblast growth factor-receptor; colony stimulating growth factor-receptor; transforming growth factor-receptor; growth hormone-receptor; parathyroid hormone-receptor; calcitonin-receptor; estrogen-receptor; insulin-like growth factor serum binding protein; epidermal growth factor receptor; corticosteroid binding globulin; and bone morphogenic protein and (2) said biodegradable polymer is selected from the group consisting of alginates; hyaluronic acid and derivatives thereof: polyglycolide; copolymers of glycolide; copolymers of glycolide and L-lactide; copolymers of glycolide and trimethylene carbonate; polylactides; stereo-copolymers of polylactides; poly-L-lactide; poly-DL-lactide; copolymers of L-lactide and DL-lactide; copolymers of polylactide; copolymers of lactide and tetramethylglycolide; copolymers of lactide and trimethylene carbonate; copolymers of lactide and α-valerolactone; copolymers of lactide and ε-caprolactone; copolymers of polylactide and polyethylene oxide; copolymers of poly-β-hydroxybutyrate; polyurethanes; methylmethacrylate-N-vinyl pyrrolidone copolymers; and poly-p-dioxanone; said ligand being a ligand specific to said protein and being linked to said protein.
Claim 3
Dependent Claim
12 words
The method according to claim 1 wherein said active ingredient is IGF-1.
Claim 4
Dependent Claim
20 words
The method according to claim 1 wherein said receptor comprises the extracellular domain of the protein for binding said ligand.
Claim 5
Dependent Claim
13 words
The method according to claim 1 wherein the biodegradable polymer is hyaluronic acid.
Claim 6
Dependent Claim
11 words
The method according to claim 4 wherein the ligand is IGF-1.
Claim 7
Independent Claim
161 words
A method for administering a pharmaceutical preparation to a patient in need thereof comprising administering to said patient a slow release conjugate comprising as active ingredient a ligand selected from the group consisting of growth factors and hormones in combination with an adjuvant which controls the release of said ligand, said adjuvant selected from the group consisting of receptors for said ligand and binding proteins for said ligand, and a biodegradable polymer as carrier for said slow release conjugate, wherein said biodegradable polymer is selected from the group consisting of alginates; hyaluronic acid and derivatives thereof; polyglycolide; copolymers of glycolide; copolymers of glycolide and L-lactide; copolymers of glycolide and trimethylene carbonate; polylactides; stereo-copolymers of polylactides; poly-L-lactide: poly-DL-lactide; copolymers of L-lactide and DL-lactide; copolymers of polylactide; copolymers of lactide and tetramethylglycolide; copolymers of lactide and trimethylene carbonate; copolymers of lactide and α-valerolactone; copolymers of lactide and ε-caprolactone; copolymers of polylactide and polyethylene oxide; copolymers of poly-β-hydroxybutyrate; polyurethanes; methylmethacrylate-N-vinyl pyrrolidone copolymers; and poly-p-dioxanone.
Claim 8
Independent Claim
161 words
A method for administering a pharmaceutical preparation to a patient in need thereof comprising administering to said patient a slow release conjugate comprising as active ingredient a ligand selected from the group consisting of growth factors and hormones in combination with an adjuvant which controls the release of said ligand, said adjuvant selected from the group consisting of receptors for said ligand and binding proteins for said ligand, and a biodegradable polymer as carrier for said slow release conjugate, wherein said biodegradable polymer is selected from the group consisting of alginates; hyaluronic acid and derivatives thereof; polyglycolide; copolymers of glycolide; copolymers of glycolide and L-lactide; copolymers of glycolide and trimethylene carbonate; polylactides; stereo-copolymers of polylactides; poly-L-lactide: poly-DL-lactide; copolymers of L-lactide and DL-lactide; copolymers of polylactide; copolymers of lactide and tetramethylglycolide; copolymers of lactide and trimethylene carbonate; copolymers of lactide and α-valerolactone; copolymers of lactide and ε-caprolactone; copolymers of polylactide and polyethylene oxide; copolymers of poly-β-hydroxybutyrate; polyurethanes; methylmethacrylate-N-vinyl pyrrolidone copolymers; and poly-p-dioxanone.
Claim 9
Dependent Claim
15 words
The method according to claim 6 wherein said receptor is conjugated to said biodegradable polymer.
Claim 10
Dependent Claim
50 words
The method according to claim 6 wherein said ligand is selected from the group consisting of insulin-like growth factor-1; insulin-like growth factor-2; platelet-derived growth factor; epidermal growth factor; erythropoietin; fibroblast growth factor; colony stimulating factor; transforming growth factor; calcitonin; parathyroid hormone; growth hormone; estrogens; bone morphogenic protein; corticosteroids; and insulin.
Claim 11
Dependent Claim
28 words
The method according to claim 6 wherein said receptor comprises the extracellular domain of said receptor or said binding protein comprises the extracellular domain of said binding protein.
References Cited (Backward Citations)
US4469681A
Cited
US4636424A
Cited
US4828563A
Cited
EP0224987A2
Cited
US4957744A
Cited
US5252713A
Cited
US4992378A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-11-27 | 1999-05-29 | 1999-11-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-11-27 | 2003-05-29 | 2003-11-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-11-27 | 2007-05-29 | 2007-11-28 | $7700.00 | Window Closed / Lapsed |